{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:03Z","timestamp":1786119243604,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/qai.0b013e3181aa12d5","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T05:07:16Z","timestamp":1245647236000},"page":"290-297","source":"Crossref","is-referenced-by-count":63,"title":["A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir\/Lamivudine or Tenofovir\/Emtricitabine in HIV-1-Infected Patients With Virological Suppression"],"prefix":"10.1097","volume":"51","author":[{"given":"Esteban","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Lonc\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Cos\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Barrufet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Pich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cruceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan A","family":"Arnaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210131","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1157\/13096750","article-title":"Recomendaciones de GESIDA\/Plan nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana: actualizacion enero de 2007.","volume":"25","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R3-8-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1293.2007.00533.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults in Europe.","volume":"9","author":"Clumeck","year":"2008","journal-title":"HIV Med"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkl191","article-title":"Benefits and concerns of simplication strategies in HIV-infected patients.","volume":"58","author":"Negredo","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R8-8-20210131","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"R9-8-20210131","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Therapy\/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0149-2918(02)85132-3","article-title":"Risk factor analysis of hypersensitivity reactions to abacavir.","volume":"24","author":"Symonds","year":"2002","journal-title":"Clin Ther"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"R17-8-20210131","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"R18-8-20210131","first-page":"1","article-title":"MMWR Recomm Rep.","volume":"41","year":"1992","journal-title":""},{"key":"R19-8-20210131","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/(SICI)1097-0258(19980630)17:12<1403::AID-SIM834>3.0.CO;2-Y","article-title":"Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies.","volume":"17","author":"Chan","year":"1998","journal-title":"Stat Med"},{"key":"R20-8-20210131","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-8-20210131","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/00002030-200311210-00007","article-title":"Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.","volume":"17","author":"Bucher","year":"2003","journal-title":"AIDS"},{"key":"R22-8-20210131","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virological suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R24-8-20210131","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00002030-200402200-00012","article-title":"Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.","volume":"18","author":"Negredo","year":"2004","journal-title":"AIDS"},{"key":"R25-8-20210131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.aids.0000163933.14649.93","article-title":"Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.","volume":"19","author":"Barrios","year":"2005","journal-title":"AIDS"},{"key":"R26-8-20210131","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/135965350701200602","article-title":"CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.","volume":"12","author":"Wolbers","year":"2007","journal-title":"Antiv Ther"},{"key":"R28-8-20210131","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R29-8-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R30-8-20210131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R31-8-20210131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A once-daily lopinavir\/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.","volume":"43","author":"Johnson","year":"2006","journal-title":"J Acquir immune Defic Syndr"},{"key":"R32-8-20210131","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.aids.0000216371.76689.63","article-title":"96-week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virological failures.","volume":"20","author":"Johnson","year":"2006","journal-title":"AIDS"},{"key":"R34-8-20210131","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for thymidine analogue in persons with lipoatrophy.","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200907010-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:19Z","timestamp":1786038799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200907010-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181aa12d5","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}